5/21/2019

2% Lidocaine Hydrochloride Topical Jelly

Reason for the Shortage

- Akorn has 2% lidocaine jelly available.
- Teva discontinued lidocaine jelly in early-2018.
- Glydo and Uro-Jet prefilled syringes are not affected by this shortage.

Available Products

- Lidocaine Hydrochloride topical jelly, Akorn, 2%, 30 mL tube, 1 count, NDC 17478-0711-30
- Lidocaine Hydrochloride topical jelly, Akorn, 2%, 5 mL tube, 10 count, NDC 17478-0711-10

Estimated Resupply Dates

- Akorn has 2% lidocaine jelly 5 mL and 30 mL tubes available.

Updated

Updated May 21, 2019 by Michelle Wheeler, PharmD, Drug Information Specialist. Created February 22, 2018 by Leslie Jensen, PharmD, Drug Information Specialist. © 2019, Drug Information Service, University of Utah, Salt Lake City, UT.

Disclaimer

Drug Shortage Bulletins are copyrighted by the Drug Information Service of the University of Utah and provided by ASHP as its exclusive authorized distributor. ASHP and the University of Utah make no representations or warranties, express or implied, including, but not limited to, any implied warranty of merchantability and/or fitness for a particular purpose, with respect to such information, and specifically disclaim all such warranties. Users of this information are advised that decisions regarding the use of drugs and drug therapies are complex medical decisions and that in using this information, each user must exercise his or her own independent professional judgment. Neither ASHP nor the University of Utah assumes any liability for persons administering or receiving drugs or other medical care in reliance upon this information, or otherwise in connection with this Bulletin. Neither ASHP nor the University of Utah endorses or recommends the use of any particular drug. Any application of this information for any purpose shall be limited to personal, non-commercial use.

« Back to Drug Shortage Product Bulletins

Subscribe to AHFS Clinical Drug Information to get direct access to integrated drug shortages content, plus comprehensive and actionable drug information.